Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 53: 1985-1986, 2007; 10.1373/clinchem.2007.093377
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daval, S.
Right arrow Articles by Evrard, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daval, S.
Right arrow Articles by Evrard, B.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2007;53:1985-1986.)
© 2007 American Association for Clinical Chemistry, Inc.


Letters to the Editor

Risk of Antigen Excess in Serum Free Light Chain Measurements

Sandrine Daval1,1, Arlette Tridon1,2,1, Nicole Mazeron1, Jean-Michel Ristori2,3 and Bertrand Evrard1,2,a

1 Centre Hospitalier Universitaire Clermont-Ferrand Department of Immunology Hotel-Dieu Hospital Clermont-Ferrand, France
2 Université Clermont1 Faculty of Medicine-Pharmacy Clermont-Ferrand, France
3 Centre Hospitalier Universitaire Clermont-Ferrand Department of Rheumatology G Montpied Hospital Clermont-Ferrand, France

aAddress correspondence to this author at: Department of Immunology, Hotel-Dieu, Blvd. Leon Malfreyt, F-63058 Clermont-Ferrand, France. Fax 33-4-73-750-637; e-mail bevrard{at}chu-clermontferrand.fr.


To the Editor:

Measurement of immunoglobulin {kappa} and {lambda} free light chains (FLC) has improved the diagnostic evaluation and monitoring of monoclonal gammopathies (1), particularly light chain multiple myeloma(2), nonsecretory multiple myeloma, plasmacytoma, systemic amyloid light chain (AL) amyloidosis, heavy chain myeloma(3), and monoclonal gammopathy of undetermined significance(4). FLC measurement methods, however, are affected by analytical problems inherent to nephelometric techniques.

A 76-year-old woman was admitted for evaluation of bone pain and hypercalcemia. The pains were located in the left inguinal fold. Examination showed no lymphadenopathy or hepatosplenomegaly. X-rays of the skeleton showed 2 voluminous gaps in the pubic branches. Laboratory examinations showed hypercalcemia of 2.91 mmol/L and renal insufficiency. Complete blood cell count showed a macrocytic anemia with a hemoglobin concentration of 97 g/L, rouleaux formation, and circulating plasmacytes. Bone marrow contained 85% dystrophic plasmacytes. Serum total protein was 68 g/L. Protein electrophoresis showed hypogammaglobulinemia of 2.2 g/L [reference interval (RI) 7–11 g/L] with a moderate increase of the {alpha}-2 fraction (12.2 g/L, RI, 6–9 g/L). Immunofixation electrophoresis of blood and urine showed a major band of monoclonal {kappa} FLC migrating in the {alpha}-2 region. Serum FLC measurement showed a major increase in the {kappa} FLC (Table 1 ). We arrived at a diagnosis of light chain {kappa} multiple myeloma.


View this table:
[in this window]
[in a new window]

 
Table 1. Serum FLC measurements according to the dilutions.

In our laboratory, serum {kappa} and {lambda} FLC measurements are carried out with a nephelometric technique on the BNprospec automat (Dade Behring) using the Freelite reagents (The Binding Site) according to the manufacturer’s recommendations. A 1st FLC measurement is recommended on a sample diluted at 1:100. If the result is lower than the low end of the assay range, the machine automatically starts the assay again by diluting at 1:20 and then at 1:5. Likewise, if the concentration in FLC is higher than the high value of the range, the analyzer automatically starts serial dilutions and continues to a dilution of 1:32 000.

Initially, the {kappa} chains were <0.294 mg/L [RI, 3.3–19.4 mg/L (5)] and {lambda} chains were <0.405 mg/L [RI, 5.7–26.3 mg/L(5)]. In view of this unusual result (double negativity), a 1:32 000 dilution was made manually and the {kappa}-chain concentrations were then >60 100 mg/L. Measurement at a dilution of 1:2000 was then carried out for the {lambda} chains, and the result was <0.41 mg/L (Table 1Up ). Serum immunofixation confirmed the result, with a strong {kappa} monoclonal band. Thirty-five days later the {kappa} chains were 112 mg/L and {lambda} chains <0.405 mg/L. Given the patient’s history, however, a measurement at a dilution of 1:32 000 was made manually for {kappa} FLC, and the concentration obtained was 12 600 mg/L (Table 1Up ).

In this patient, we repeatedly observed that very high FLC concentrations yielded paradoxically low results. This situation is consistent with antigen excess. The "limitations" section of the product insert from the company does alert the user to the possibility of this phenomenon, but to our knowledge this report is the 1st to demonstrate that the problem of antigen excess in this assay is not merely theoretical but can actually occur clinically. The main risk is that a value within the RI, or one that is substantially underestimated, will be reported instead of the true value. To eradicate antigen excess, any suspect sample must be tested again at a higher dilution. Serum FLC measurements should always be interpreted together with other laboratory test results and clinical findings. This protocol requires a laboratory capable of performing serum protein electrophoresis, immunofixation, serum FLC measurement, and measurements of IgG, -A, and -M. Dissociation of these techniques among various laboratories can cause errors in interpretation.

In conclusion, we have illustrated that antigen excess can cause falsely low serum FLC results with nephelometric techniques. Clinically suspicious results should be repeated after sample dilution.


Acknowledgments

Grant/funding support: None declared.

Financial disclosures: None declared.


Footnotes

1 These authors contributed equally to this work.


References

  1. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-680.[Abstract/Free Full Text]
  2. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361:489-491.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  3. Hill PG, Forsyth JM, Rai B, Mayne S. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem 2006;52:1743-1748.[Abstract/Free Full Text]
  4. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, 3rd, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812-817.[Abstract/Free Full Text]
  5. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-1444.[Abstract/Free Full Text]



The following articles in journals at HighWire Press have cited this article:


Home page
Am J Clin PatholHome page
A. Legg, J. A. R. Hobbs, G. P. Mead, A. R. Bradwell, S. Davern, and A. Solomon
Monoclonal vs Polyclonal Free Light Chain Assays
Am J Clin Pathol, June 1, 2009; 131(6): 901 - 902.
[Full Text] [PDF]


This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Daval, S.
Right arrow Articles by Evrard, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daval, S.
Right arrow Articles by Evrard, B.
Related Collections
Right arrow Proteomics and Protein Markers


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS